She hid her young onset Parkinson's diagnosis for years. Now she's an 'unshakeable' advocate
She thought at first it was related to the pregnancy. But after further testing, she was diagnosed with Parkinson's disease. "From a medical standpoint, I accepted it, but I really didn't truly ...
imt.ie1d
New wearable device to provide 24-hour treatment to advanced Parkinson’s patients
Manufactured by AbbVie, Produodopa is a subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe ...
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments
US Neurologists express enthusiasm for new ways to administer current treatments and future disease modifying therapies, according to .Exton, Pennsylvania, May 09, 2024 (GLOBE NEWSWIRE) -- Even as the ...
Buy Rating Affirmed for Trevi Therapeutics Amid Promising Clinical Advances and Solid Financial Position
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on TRVI stock, giving a Buy rating yesterday. Thomas Smith has given ...
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript
Q1 2024 Earnings Call Transcript May 8, 2024 ACADIA Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge ...
clinicaladvisor.com2d
Lixisenatide Decreases Motor Disability Progression in Early Parkinson Disease
Among the lixisenatide and placebo groups, 100% and 97% were receiving levodopa, 45% and 41% were receiving monoamine oxidase B inhibitors, and 69% and 78% were receiving dopamine agonist, ...
Supernus Announces First Quarter 2024 Financial Results
Net sales of Qelbree® increased 75% to $45.1 million compared to first quarter 2023.Total revenues were $143.6 million. Total revenues excluding ...
The Globe and Mail2d
Knight Therapeutics Reports First Quarter 2024 Results
During the quarter, Knight in-licensed IPX203 for Canada and Latin America. IPX203 is a novel, oral formulation of carbidopa/levodopa ("CD/LD") extended-release capsules designed for the treatment of ...
She had Parkinson's and didn't want to live. Then she got this surgery.
Deep brain stimulation is a game-changer for patients like Peters amid the ongoing fight for medical breakthroughs for neurologic conditions.
PharmiWeb4d
IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLYGOTHENBURG, SE / ACCESSWIRE / May 7, 2024 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, ...
PharmiWeb5d
IRLAB: Invitation to the Interim Report for Q1 2024 Presentation and Webcast
GOTHENBURG, SWEDEN / ACCESSWIRE / May 6, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 6, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and ...